PURPOSE: Common treatments for benign prostatic hyperplasia include 5α-reductase inhibitors and α-adrenergic receptor antagonists. However, these treatments can only partially decrease the risk of benign prostatic hyperplasia progression. SRD5A1 and SRD5A2 are 5α-reductase inhibitor targets. We investigated the association between drug efficacy and single nucleotide polymorphisms in the SRD5A1 and SRD5A2 genes in a Chinese population. MATERIALS AND METHODS: We genotyped 11 tagging single nucleotide polymorphisms in the SRD5A1 and SRD5A2 genes in a total of 426 benign prostatic hyperplasia cases and 1,008 controls from Xinhua Hospital, Shanghai, People's Republic of China. Cases were treated with type II 5α-reductase inhibitors and α-adrenergic receptor antagonists. We tested the association of tagging single nucleotide polymorphisms with benign prostatic hyperplasia risk/progression, clinical characteristics at baseline, including the I-PSS (International Prostate Symptom Score) and total prostate volume, and changes in clinical characteristics after treatment. RESULTS: The 11 tagging single nucleotide polymorphisms were not significantly associated with benign prostatic hyperplasia risk or progression (each p >0.05). In the SRD5A1 gene rs6884552 and rs3797177 were significantly associated with baseline I-PSS (p = 0.04 and 0.003, respectively). In the SRD5A2 gene rs523349 (V89L) and rs9332975 were significantly associated with baseline total prostate volume (p = 0.01 and 0.001, respectively). In SRD5A1 rs166050 was significantly associated with the posttreatment change in total prostate volume (p = 0.04). In SRD5A2 rs523349 and rs612224 were significantly associated with the posttreatment I-PSS change (p = 0.03 and 0.009, respectively). CONCLUSIONS: SRD5A1 and SRD5A2 single nucleotide polymorphisms are significantly associated with the clinical characteristics of benign prostatic hyperplasia and the efficacy of benign prostatic hyperplasia treatment.
PURPOSE: Common treatments for benign prostatic hyperplasia include 5α-reductase inhibitors and α-adrenergic receptor antagonists. However, these treatments can only partially decrease the risk of benign prostatic hyperplasia progression. SRD5A1 and SRD5A2 are 5α-reductase inhibitor targets. We investigated the association between drug efficacy and single nucleotide polymorphisms in the SRD5A1 and SRD5A2 genes in a Chinese population. MATERIALS AND METHODS: We genotyped 11 tagging single nucleotide polymorphisms in the SRD5A1 and SRD5A2 genes in a total of 426 benign prostatic hyperplasia cases and 1,008 controls from Xinhua Hospital, Shanghai, People's Republic of China. Cases were treated with type II 5α-reductase inhibitors and α-adrenergic receptor antagonists. We tested the association of tagging single nucleotide polymorphisms with benign prostatic hyperplasia risk/progression, clinical characteristics at baseline, including the I-PSS (International Prostate Symptom Score) and total prostate volume, and changes in clinical characteristics after treatment. RESULTS: The 11 tagging single nucleotide polymorphisms were not significantly associated with benign prostatic hyperplasia risk or progression (each p >0.05). In the SRD5A1 gene rs6884552 and rs3797177 were significantly associated with baseline I-PSS (p = 0.04 and 0.003, respectively). In the SRD5A2 gene rs523349 (V89L) and rs9332975 were significantly associated with baseline total prostate volume (p = 0.01 and 0.001, respectively). In SRD5A1rs166050 was significantly associated with the posttreatment change in total prostate volume (p = 0.04). In SRD5A2rs523349 and rs612224 were significantly associated with the posttreatment I-PSS change (p = 0.03 and 0.009, respectively). CONCLUSIONS:SRD5A1 and SRD5A2 single nucleotide polymorphisms are significantly associated with the clinical characteristics of benign prostatic hyperplasia and the efficacy of benign prostatic hyperplasia treatment.
Authors: Aleksandra Rył; Iwona Rotter; Anna Grzywacz; Iwona Małecka; Karolina Skonieczna-Żydecka; Katarzyna Grzesiak; Marcin Słojewski; Aleksandra Szylińska; Olimpia Sipak-Szmigiel; Małgorzata Piasecka; Kinga Walczakiewicz; Maria Laszczyńska Journal: Int J Environ Res Public Health Date: 2017-10-30 Impact factor: 3.390
Authors: Jacklyn N Hellwege; Sarah Stallings; Eric S Torstenson; Robert Carroll; Kenneth M Borthwick; Murray H Brilliant; David Crosslin; Adam Gordon; George Hripcsak; Gail P Jarvik; James G Linneman; Parimala Devi; Peggy L Peissig; Patrick A M Sleiman; Hakon Hakonarson; Marylyn D Ritchie; Shefali Setia Verma; Ning Shang; Josh C Denny; Dan M Roden; Digna R Velez Edwards; Todd L Edwards Journal: Sci Rep Date: 2019-04-15 Impact factor: 4.379
Authors: Xin Gu; Tao Huang; Ding Xu; Liujian Duan; Yang Jiao; Jian Kang; S Lilly Zheng; Jianfeng Xu; Jielin Sun; Jun Qi Journal: Biochem Res Int Date: 2013-08-01